9230110F15Rik Inhibitors
Chemical inhibitors of prostate and testis expressed 5 can act through a variety of biochemical mechanisms to diminish the activity of this protein. For instance, Fulvestrant binds to estrogen receptors that are necessary for the stabilization and function of prostate and testis expressed 5. By accelerating the degradation of these receptors, Fulvestrant ensures that the necessary receptor-mediated stabilization of prostate and testis expressed 5 does not occur, leading to a reduction in its activity. Similarly, Bicalutamide, Enzalutamide, Apalutamide, Darolutamide, Flutamide, and Nilutamide, all function as androgen receptor antagonists. These chemicals inhibit the androgen receptor signaling pathways that regulate the expression and functionality of prostate and testis expressed 5. By blocking this critical signaling, these antagonists effectively diminish the activity of prostate and testis expressed 5.
Furthermore, the action of Zoledronic Acid on the mevalonate pathway plays a significant role in the inhibition of prostate and testis expressed 5. By inhibiting farnesyl pyrophosphate synthase, Zoledronic Acid prevents the post-translational prenylation of small GTPase proteins, which are integral to the signaling pathways utilized by prostate and testis expressed 5. Without prenylation, these proteins cannot properly function, thereby reducing the activity of prostate and testis expressed 5. Mitoxantrone, by intercalating DNA and impeding the function of topoisomerase II, also contributes to the inhibition of prostate and testis expressed 5 by disrupting its interactions during cell proliferation. Meanwhile, Leuprorelin, Abiraterone, and Degarelix affect the upstream hormonal regulation. Leuprorelin and Degarelix, by acting respectively as an agonist and antagonist of gonadotropin-releasing hormone, downregulate the androgen receptor pathway. Abiraterone inhibits cytochrome P450 17A1, which is necessary for androgen biosynthesis that indirectly supports prostate and testis expressed 5 signaling pathways. Through these diverse mechanisms, the activity of prostate and testis expressed 5 can be substantially decreased.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ICI 182,780 | 129453-61-8 | sc-203435 sc-203435A | 1 mg 10 mg | $83.00 $187.00 | 34 | |
This chemical binds to and accelerates the degradation of estrogen receptors, which prostate and testis expressed 5 requires for its stabilization and function. Inhibition of estrogen receptors leads to a decrease in prostate and testis expressed 5 activity due to a lack of receptor-mediated stabilization. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
It inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, which is essential for post-translational prenylation of small GTPase proteins. These proteins are involved in the signaling pathways that prostate and testis expressed 5 participates in, and their inhibition can decrease prostate and testis expressed 5 activity. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $285.00 | 8 | |
This chemical intercalates DNA and inhibits topoisomerase II, an enzyme that prostate and testis expressed 5 may interact with during cell proliferation. Inhibiting topoisomerase II can prevent prostate and testis expressed 5 from exerting its effects on cell cycle progression. | ||||||
Bicalutamide | 90357-06-5 | sc-202976 sc-202976A | 100 mg 500 mg | $42.00 $146.00 | 27 | |
It acts as an androgen receptor antagonist, blocking the androgen receptor signaling that can regulate the expression and function of prostate and testis expressed 5. By inhibiting this signaling, bicalutamide can reduce the functional activity of prostate and testis expressed 5. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
Similar to bicalutamide, enzalutamide is a more potent androgen receptor antagonist that can inhibit the signaling required for prostate and testis expressed 5 functionality. Enzalutamide's inhibition of androgen receptor signaling can lead to decreased prostate and testis expressed 5 activity. | ||||||
Abiraterone | 154229-19-3 | sc-460288 | 10 mg | $276.00 | ||
It inhibits cytochrome P450 17A1, an enzyme crucial for androgen biosynthesis that indirectly supports the signaling pathways involving prostate and testis expressed 5. Inhibition of androgen biosynthesis by abiraterone can lead to decreased activity of prostate and testis expressed 5. | ||||||
Apalutamide | 956104-40-8 | sc-507442 | 5 mg | $290.00 | ||
This nonsteroidal antiandrogen competitively inhibits androgen receptors, which are involved in the regulation of prostate and testis expressed 5. By blocking androgen receptor signaling, apalutamide can inhibit the activity of prostate and testis expressed 5. | ||||||
Darolutamide | 1297538-32-9 | sc-507537 | 10 mg | $250.00 | ||
It functions as an androgen receptor antagonist and inhibits the receptor signaling that promotes the activity of prostate and testis expressed 5. Through this inhibition, darolutamide can decrease the functional activity of prostate and testis expressed 5. | ||||||
Flutamide | 13311-84-7 | sc-204757 sc-204757A sc-204757D sc-204757B sc-204757C | 1 g 5 g 25 g 500 g 1 kg | $47.00 $156.00 $171.00 $525.00 $941.00 | 4 | |
Acting as an androgen receptor antagonist, flutamide can inhibit androgen receptor-mediated signaling pathways that are necessary for the function of prostate and testis expressed 5. Inhibition of these pathways can lead to decreased prostate and testis expressed 5 activity. | ||||||